OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Company is invited to present the latest progress on its bispecific antibody checkpoint inhibitor BiCKI® platform, and in particular on its bifunctional therapy targeting PD-1 and the Interleukin-7 (IL-7) cytokine, BiCKI®-IL-7, during a plenary oral presentation in an educational session dedicated to immunocytokines at the American Association Cancer for Research (AACR) annual meeting.
April 4, 2022
· 7 min read